2,220 Stryker Corporation $SYK Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors lessened its position in Stryker Corporation (NYSE:SYK) by 56.1% in the third quarter, HoldingsChannel.com reports. The fund owned 1,740 shares of the medical technology company’s stock after selling 2,220 shares during the period. Kelleher Financial Advisors’ holdings in Stryker were worth $479,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SYK. Focused Wealth Management Inc raised its stake in Stryker by 28.5% in the third quarter. Focused Wealth Management Inc now owns 1,191 shares of the medical technology company’s stock valued at $328,000 after buying an additional 264 shares during the period. Rakuten Investment Management Inc. boosted its stake in shares of Stryker by 10.6% during the 3rd quarter. Rakuten Investment Management Inc. now owns 62,389 shares of the medical technology company’s stock worth $17,392,000 after acquiring an additional 5,976 shares during the period. AIA Group Ltd boosted its stake in shares of Stryker by 230.4% during the 3rd quarter. AIA Group Ltd now owns 46,593 shares of the medical technology company’s stock worth $12,831,000 after acquiring an additional 32,493 shares during the period. Provenance Wealth Advisors LLC boosted its stake in shares of Stryker by 1,376.5% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 3,455 shares of the medical technology company’s stock worth $951,000 after acquiring an additional 3,221 shares during the period. Finally, Associated Banc Corp acquired a new position in shares of Stryker during the 3rd quarter worth approximately $5,488,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. Raymond James Financial restated an “outperform” rating and issued a $323.00 price target (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Barclays reduced their price objective on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Stifel Nicolaus decreased their price objective on shares of Stryker from $330.00 to $325.00 and set a “buy” rating on the stock in a report on Monday. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, TD Cowen cut their target price on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a research note on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $343.73.

Stryker Price Performance

Stryker stock opened at $340.39 on Thursday. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The stock’s 50 day moving average is $292.21 and its 200-day moving average is $323.91. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $129.59 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The business’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the previous year, the business posted $3.19 earnings per share. Equities research analysts expect that Stryker Corporation will post 14.85 EPS for the current year.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.